Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab Combined With Sintilimab and SOX in pMMR/MSS Gastric Cancer
NCT07621562Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafolecimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 6 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tafolecimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07621562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621562.